CD19在儿童B系急性淋巴细胞白血病诊治中的意义与相关研究进展  

Progress and significance of CD19 in diagnosis and treatment of Blineage acute lymphoblastic leukemia in children

作　　者：乔晓红[1] Qiao Xiaohong(Department of Pediatrics, Tongji Hospital Affiliated to Tongji University, Shanghai Tongji Hospital, Shanghai 200065, China)

机构地区：[1]同济大学附属同济医院,上海市同济医院儿科200065

出　　处：《中华实用儿科临床杂志》2019年第3期170-174,共5页Chinese Journal of Applied Clinical Pediatrics

摘　　要：复发难治B系急性淋巴细胞白血病是儿童白血病相关死亡的重要原因。CD19作为治疗B淋巴细胞恶性肿瘤的潜在靶点近年备受关注。以嵌合抗原受体T淋巴细胞(CAR-T)在儿童B系急性淋巴细胞白血病临床试验中疗效显著。取得疗效的同时,需注意存在细胞因子释放综合征、严重神经毒性、心肌毒性、脱靶效应及复发等多种问题,优化CAR-T细胞的设计、合理的预处理和细胞输注方案,同时注意并发症防治,进一步提高CD19 CAR-T细胞治疗的安全性和有效性,为儿童难治复发急性淋巴细胞白血病治疗提供新方案。Relapsed and refractory Blineage acute lymphoblastic leukemia is an important cause of leukemia related death in children.CD19 as a potential target for the treatment of B cell malignancies has attracted much attention in recent years.T cells modified by chimeric antigen receptor (CAR-T) have a significant effect in the clinical trials of Blineage acute lymphoblastic leukemia in children.At the same time, doctors should pay attention to many problems, such as cytokine release syndrome, severe neurotoxicity, myocardial toxicity.Optimize the design of CAR-T cells, reasonable preconditioning and cell infusion scheme, and pay attention to the prevention and treatment of complications, maybe further improve the safety of CD19 CAR-T cell therapy.

关 键 词：急性淋巴细胞白血病 CD19 嵌合抗原受体T淋巴细胞 儿童 

分 类 号：R733.71[医药卫生—肿瘤]